Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Sep;67(17):1849-55.
doi: 10.1016/j.phytochem.2006.06.020. Epub 2006 Jul 31.

Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives

Dale G Nagle  1 , Daneel Ferreira, Yu-Dong Zhou
Affiliations
Review

Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives

Dale G Nagle et al. Phytochemistry. 2006 Sep.

Abstract

The compound (-)-epigallocatechin-3-gallate (EGCG) is the major catechin found in green tea [Camellia sinensis L. Ktze. (Theaceae)]. This polyphenolic compound and several related catechins are believed to be responsible for the health benefits associated with the consumption of green tea. The potential health benefits ascribed to green tea and EGCG include antioxidant effects, cancer chemoprevention, improving cardiovascular health, enhancing weight loss, protecting the skin from the damage caused by ionizing radiation, and others. The compound EGCG has been shown to regulate dozens of disease-specific molecular targets. Many of these molecular targets are only affected by concentrations of EGCG that are far above the levels achieved by either drinking green tea or consuming moderate doses of green tea extract-based dietary supplements. In spite of this, well-designed double-blinded controlled clinical studies have recently demonstrated the efficacy of green tea extracts and purified EGCG products in patients. Therefore, this review highlights results from what the authors believe to be some of the most clinically significant recent studies and describes current developments in the stereoselective total synthesis of EGCG.

PubMed Disclaimer

Figures

Scheme 1
Scheme 1
Reagents and conditions: i) Pd-H2/EtOH, then NaBH4/EtOH; ii) SOCl2, then 1,8-DBU/CH2Cl2, reflux; iii) AD-mix-α, ButOH/H2O (1:1 v/v), MeSO2NH2, 0° C; iv) 3M HCl, MeOH/H2O (3:1 v/v).
Scheme 2
Scheme 2
Reagents and conditions: i) H2SO4(SiO2)/CH2Cl2/CS2/rt; ii) TBDMSCl/imidazole/DMF, rt; iii) AD-mix-α/CH3SO2NH2/H2O/t-BuOH, 0° C; iv) TBAF/THF, rt; v) CH(OEt)3/PPTS/CH2Cl2, rt; vi) Dess-Martin periodinane/CH2Cl2, rt; vii) L-selectride/THF, -78°C→ rt; viii) 3,4,5-tris(benzyloxy)benzoyl chloride/DMAP/CH2Cl2, rt; ix) H2/Pd(OH)2/MeOH/THF, rt.
Scheme 3
Scheme 3
Reagents and conditions: i) NBS/AIBN in CCl4, reflux; ii) NaB3H4/MeOH, rt, then NaBH4/MeOH
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abe I, Seki T, Umehara K, Miyase T, Noguchi H, Sakakibara J, Ono T. Green tea polyphenols: novel and potent inhibitors of squalene epoxidase. Biochem. Biophys. Res. Commun. 2000;268:767–771. - PubMed
    1. Adhami VM, Ahmad N, Mukhtar H. Molecular targets for green tea in prostate cancer prevention. J. Nutr. 2003;133(Suppl.):2417S–2424S. - PubMed
    1. Ahn W-S, Huh SW, Bae S-M, Lee I-P, Lee J-M, Namkoong S-E, Kim C-K, Sin J-I. A major constituent of green tea, EGCG, inhibits the growth of a human cervical cancer cell line, CaSki cells, through apoptosis, G(1) arrest, and regulation of gene expression. DNA Cell Biol. 2003a;22:217–224. - PubMed
    1. Ahn W-S, Yoo J, Huh SW, Kim C-K, Lee J-M, Namkoong S-E, Bae S-M, Lee IP. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur. J. Cancer Prev. 2003b;12:383–390. - PubMed
    1. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res. 2006;66:1234–1240. - PubMed

Publication types

-